Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
This is the first modern study (n=12) on psilocybin and its effects on treatment-resistant depression (TRD). It shows that two sessions with psilocybin (10mg and 25mg) in combination with psychological support can reduce depressive symptoms over periods of one week to three months after treatment. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred.
Authors
- James Rucker
- Robin Carhart-Harris
- David Nutt
Published
Abstract
Background
Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression.
Methods
In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was the patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797.
Findings
Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference −11·8, 95% CI −9·15 to −14·35, p=0·002, Hedges' g=3·1) and 3 months (−9·2, 95% CI −5·69 to −12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted.
Interpretation
This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.
Research Summary of 'Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study'
βBlossom's Take
Introduction
Psilocybin is a naturally occurring psychedelic prodrug of psilocin that produces its principal psychoactive effects via serotonin 2A (5-HT2A) receptor agonism. Earlier preclinical and human imaging work has linked 5-HT2A receptor agonism with cognitive and neural plasticity changes and with antidepressant-like effects, and modern clinical studies of psychedelics have reported reductions in anxiety, depressive symptoms, and addictive behaviours after one or two exposures. At the same time, depression remains a major global health burden and a substantial minority of patients do not respond to available treatments, creating a need for new interventions for treatment-resistant depression. Carhart-Harris and colleagues designed this open-label feasibility study to assess whether a protocol of two supervised oral psilocybin administrations, given with psychological support, could be safely delivered to patients with unipolar treatment-resistant major depression and to obtain an initial impression of clinical effects. Their prespecified primary feasibility outcome was patient-rated subjective intensity of psilocybin's effects; the principal efficacy endpoint was change in self-reported depressive symptoms (16-item QIDS) from baseline to 1 week after the high-dose session. The investigators hypothesised that the intervention would be well tolerated and produce substantial reductions in depressive symptoms lasting up to 3 months.
Methods
This was an open-label, single-arm feasibility trial with no control group and no masking of participants, investigators, raters, or statisticians. The intended recruitment for the imaging protocol was 20 patients, but the present report covers the first 12 participants enrolled. Inclusion criteria required major depression of moderate to severe degree (HAM-D ≥17) and failure to improve after at least two adequate antidepressant courses of different pharmacological classes during the current episode. Exclusion criteria included current or past psychotic disorder, a first-degree relative with a psychotic disorder, medically significant conditions, history of serious suicide attempts requiring hospitalisation, history of mania, blood or needle phobia, pregnancy, and current drug or alcohol dependence. Recruitment was via general practitioner networks and self-referral; in every case the patient's clinician provided written documentation of diagnosis and history. Procedures combined preparatory psychological work, two dosing sessions separated by 7 days, and follow-up. After medical screening (ECG, blood tests, vitals) and a baseline 60-minute fMRI scan, patients undertook an extensive preparatory psychological session (typically about 4 hours) with the two psychiatrists who would provide support. Dosing occurred in a calm, music-supported clinical room with at least two staff present. Patients received an initial low oral dose of psilocybin 10 mg and, 7 days later, a treatment dose of 25 mg. Physiological monitoring and observer ratings of acute effects were recorded at baseline and at multiple timepoints up to 360 minutes postdose; subjective altered-state effects were assessed 6–7 hours after dosing using the 11-dimension ASC questionnaire. Tranquillising medications (oral lorazepam and risperidone) were available but not used. Follow-up included a telephone check 1 day after the low dose, a posttreatment fMRI and clinical assessment 1 day after the high dose, an in-person 1-week follow-up with repeat assessments and debriefing, email-based clinical questionnaires at 2, 3, and 5 weeks (QIDS only), and a final remote assessment at 3 months that included QIDS, BDI, STAI-T, and SHAPS. The primary feasibility outcome was patient-rated subjective intensity of psilocybin on a 0–1 scale. The primary efficacy outcome was mean change in QIDS from baseline to 1 week after the high-dose session; secondary measures included BDI, STAI-T, SHAPS, HAM-D, MADRS, and GAF at specified timepoints. No formal power calculation was performed for this feasibility report; statistical analyses used two-tailed Wilcoxon signed-rank tests for non-parametric comparisons and two-tailed t tests where appropriate, with 95% confidence intervals reported for mean differences.
Results
Between May and August 2015, 72 people were initially considered, 38 underwent telephone screening, 18 were invited for formal screening, and 12 patients were ultimately enrolled (ten self-referrals). Baseline clinical severity was high: nine of 12 met criteria for severe or very severe depression (BDI ≥30) and the remaining three met criteria for moderate depression (BDI 19 to <30). Most participants (11 of 12) had received prior psychotherapy. All participants completed the two-dose protocol. Mean self-rated intensity of the psilocybin experience was 0.51 (SD 0.36) for the 10 mg session and 0.75 (SD 0.27) for the 25 mg session. Acute psychedelic effects typically emerged between 30 and 60 minutes, peaked between 2 and 3 hours, and subsided to negligible levels by about 6 hours, at which point discharge assessment occurred. No participant required the available tranquilising medications. Adverse events were generally transient and expected: mild transient anxiety at onset (n=12), transient confusion or thought disorder (n=9), mild transient nausea (n=4), and transient headache (n=4). One patient experienced mild, transient paranoia. No prolonged psychotic symptoms or serious or unexpected adverse events were observed. During 3 months of follow-up one participant contacted the study psychiatrists for deteriorating depression and was referred back to their general practitioner. Clinically, self-reported depressive symptoms (QIDS) were significantly reduced relative to baseline at 1 week and at 3 months after the high-dose session, with the largest mean effect observed at 2 weeks. BDI and clinician-administered ratings (HAM-D, MADRS, GAF) confirmed these improvements at 1 week. By standard remission criteria on the BDI (score ≤9), eight of 12 patients (67%) achieved complete remission at 1 week. At 3 months, seven patients (58%) continued to meet response criteria (≥50% reduction in BDI from baseline), and five patients (42%) remained in complete remission. Anxiety (STAI-T) and anhedonia (SHAPS) scores were also significantly reduced at both 1 week and 3 months. The investigators noted that while all patients showed some improvement for at least 3 weeks, five participants displayed a degree of relapse by 3 months.
Discussion
Carhart-Harris and colleagues interpret these findings as supportive of the feasibility and tolerability of supervised psilocybin administration with psychological support in people with unipolar treatment-resistant depression, and they regard the observed reductions in depressive symptoms as sufficient to justify further controlled research. The reported 1-week response/remission rates (67% remission on BDI at 1 week) and the persistence of response in a majority at 3 months are highlighted as notable, particularly given the long illness durations in this sample. The investigators position these results within prior psychedelic literature showing rapid and sustained improvements after one or two administrations in conditions such as end-of-life anxiety, substance dependence, and smoking cessation. They note that psilocybin's pharmacology (direct 5-HT2A agonism) differs from current antidepressants and might underlie distinct therapeutic mechanisms. Key limitations acknowledged by the authors include the open-label, single-arm design and small sample size, which preclude strong efficacy conclusions and leave the results vulnerable to expectancy and self-selection biases, especially since most participants self-referred. The combination of drug administration and substantial psychological support and a positive therapeutic setting makes it impossible in this design to disentangle the relative contributions of pharmacology versus contextual and psychotherapeutic factors. The authors also caution about inflated effect sizes in early-phase trials and note that five participants showed partial relapse by 3 months. Practical considerations for future trials include the likely need to control for concomitant serotonergic antidepressants, since chronic SSRI use can downregulate 5-HT2A receptors and attenuate psychedelic responses. For future research the authors propose randomised, placebo-controlled designs with equivalent therapist contact between arms, consideration of active placebos to preserve blinding, and comparative trials versus other rapid-acting interventions (for example, ketamine). They also suggest measuring and managing expectancy and suggestibility, which may be influential in psychedelic therapies and could be treated either as confounds or as components of the therapeutic model. Overall, the investigators conclude that their data support further rigorous trials to examine psilocybin's potential as a novel treatment for treatment-resistant depression.
View full paper sections
INTRODUCTION
Psilocybin is a naturally occurring plant alkaloid found in the Psilocybe genus of mushrooms. Psilocybe mushrooms have been used for millennia for healing purposes, but were only discovered by modern science in the late 1950s.Psilocybin is a prodrug of psilocin (4-hydroxy-dimethyltryptamine), a serotonin receptor agonist and classic psychedelic drug whose principal psychoactive eff ects are mediated by serotonin 2A (5-HT 2A ) receptor agonism.Psilocybin therefore has a novel pharmacology in the context of currently available antidepressant medications, because selective serotoninreuptake inhibitors are not direct 5-HT 2A receptor agonists. Enhanced cognitive fl exibility,associative learning, 5 cortical neural plasticity,and antidepressant responses have been reported with 5-HT 2A receptor agonism in animals,and increased and sustained improvements in wellbeingand optimismhave been observed after psychedelic experiences in human beings. Findings from human imaging studies with psilocybin have supplemented these discoveries, showing changes in brain activity suggestive of antidepressant potential; for example, a range of eff ective antidepressant treatments have been found to normalise hyperactivity in the medial prefrontal cortex and we found reduced blood fl ow in this region with intravenous psilocybin.Moreover, data obtained from large-scale population studies have recently challenged the view that psychedelics negatively aff ect mental health,with one study's fi ndings showing lower rates of psychological distress and suicidality among people who had used psychedelics within their lifetime than among those who used no psychedelics but an equivalent amount of other drugs.In modern trials, psychedelics have been found to reduce anxious,depressive,and obsessivecompulsive symptoms,as well as addictive behaviours,often for several months after just one or two exposures. Extensive historical and modern evidence now supports the view that, administered in a controlled environment with appropriate support, psychedelics have a favourable safety profi le.Depression is a major public health problem; it is a leading contributor to the global burden of disease, aff ecting hundreds of millions of people worldwide, and costing the USA alone more than US$200 billion each year.Antidepressant medications and cognitive behavioural therapy can be eff ective for some patients, but around 20% do not respond to any intervention, and many of those who do respond, eventually relapse.We aimed to investigate the safety and feasibility of psilocybin in patients with treatment-resistant depression, and to establish an initial impression of its effi cacy. We postulated that the treatment would be well tolerated and depressive symptoms would be substantially reduced from baseline at all assessment points, for up to 3 months after treatment.
STUDY DESIGN AND PARTICIPANTS
This was an open-label feasibility study in patients with treatment-resistant depression; there was no control group. Patients, invest igators, raters, and statisticians were not masked to treatment assignment, and all participants received the study intervention (psilocybin administered in two dosing sessions; an initial safety [low] dose and a subsequent treatment [high] dose). The inclusion criteria were major depression of a moderate to severe degree (17+ on the 21-item Hamilton Depression Rating scale [HAM-D]), and no improvement despite two adequate courses of antidepressant treatment of diff erent pharmacological classes lasting at least 6 weeks within the current depressive episode.Exclusion criteria were: current or previously diagnosed psychotic disorder; immediate family member with a diagnosed psychotic disorder; medically signifi cant condition rendering unsuitability for the study; history of serious suicide attempts (requiring hospitalisation); history of mania; blood or needle phobia; positive pregnancy test at screening or during the study; and current drug or alcohol dependence. Information about the study's recruitment was sent to general practitioners via the North West London Clinical Research Network. However, patients were also allowed to self-refer to the study if they were UK residents. In every case, patients initiated contact with the research team (via email, letter, or telephone), were sent a study information sheet, and a subsequent telephone screening was arranged, during which the lead psychiatrist on the trial (MBo) obtained information about the patient's demographics, medical and psychiatric history, and other key inclusion or exclusion criteria. The patient's general practitioner or psychiatrist provided written documentation of the patient's diagnosis and mental health background in every case. This trial received a favourable opinion from the National Research Ethics Service London-West London, was sponsored and approved by Imperial College London's Joint Research and Compliance Offi ce (JRCO), and was adopted by the National Institute for Health Research Clinical Research Network. The National Institute for Health Research/Wellcome Trust Imperial Clinical Research Facility gave site-specifi c approval for the study.
RESEARCH IN CONTEXT
Evidence before this study We searched PubMed up to Jan 30, 2016, using the terms "psilocybin", "hallucinogens", "psychedelics", and "depression". We did not fi nd any clinical trials assessing psilocybin as a treatment for depression, but we did fi nd population analyses, review articles, and imaging studies lending support to this approach. We also found one report documenting enduring decreases in depressive symptoms after a single dose of psilocybin in a randomised controlled trial of psilocybin-assisted psychotherapy for end-of-life anxiety, one report on an open-label trial showing rapid decreases in depressive symptoms that endured for up to 21 days after a single dose of ayahuasca, and two early reports or case studies on the eff ects of lysergic acid diethylamide on "neurotic" and depressive symptoms describing "improvements", albeit without validated measures of symptom severity.
ADDED VALUE OF THIS RESEARCH
To our knowledge, this is the fi rst investigation of the safety and effi cacy of psilocybin as a treatment for major depression. Our fi ndings imply that psilocybin might have value as a treatment option in the management of treatment-resistant depression. Single oral administrations of 10 mg (safety dose) and 25 mg (treatment dose) psilocybin were well tolerated and led to enduring reductions in symptom severity after the two sessions.
IMPLICATIONS OF ALL THE AVAILABLE EVIDENCE
The results of this small-scale feasibility study should help to motivate further research into the effi cacy of psilocybin with psychological support for major depression. Larger-scale randomised controlled trials are warranted to better examine the potential of psilocybin as a treatment option for this highly prevalent, disabling, costly, and diffi cult-to-treat disorder. More broadly, the present study should help to catalyse the re-emergence of a promising research area in psychiatry. The study was reviewed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA). All participants provided written informed consent. Study and data monitoring was carried out independently by the Imperial Clinical Research Facility and JRCO.
PROCEDURES
Psilocybin was obtained from THC-pharm (Frankfurt, Germany) and formulated into the investigational medicinal product (5 mg ). Patients also received a thorough physical health check, consisting of an electrocardiogram, routine blood tests, blood pressure, heart rate, and physical examination. At the end of screening, eligible patients were given an opportunity to meet with the two clinical psychiatrists who would support them through the remainder of the trial. Eligible patients attended a subsequent visit involving a baseline functional MRI (fMRI) scanning session lasting 60 min, followed by an extensive preparatory session with their allocated psychiatrists; fMRI data will be reported elsewhere. This preparatory session involved inviting the patient to talk openly about their personal history (including thoughts on the origins of their depression), a discussion of psilocybin's psychological eff ects, and simulation of aspects of the dosing session itself, such as listening to a sample of the session music while wearing eyeshades. The preparatory session typically lasted for 4 h, with lunch and breaks provided. Patients enrolled in the study attended two subsequent dosing sessions that were separated by 7 days. No more than one patient was dosed on any given day. Patients arrived at the research facility (Imperial Clinical Research Facility) at 0900 h, gave a urine sample for drugs of abuse (including amphetamines, benzodiazapines, opiates, and cannabinoids), performed a breathalyser test for alcohol use, and completed interim QIDS, BDI, and STAI-T assessments to ensure no substantial deviation from baseline measures. They were then taken to a dosing room that was pre-decorated (eg, with low lighting). Patients were invited to relax on a ward bed in a supine or reclined position and music was played through high-quality stereo speakers and earphones. The two psychiatrists sat on either side of the bed. Patients were supervised at all times by at least two staff members. Dosing commenced at 1030 h in every case. Patients received a low oral dose of psilocybin 10 mg (two 5 mg capsules) on a fi rst dosing day and a high oral dose of psilocybin 25 mg (fi ve 5 mg capsules) on a second dosing day, separated by 1 week. Blood pressure, heart rate, and observer ratings of the intensity of psilocybin's acute psychoactive eff ects (0-4, with 0 signifying no eff ects and 4 signifying extreme eff ects 8 ) were measured at baseline (typically 5 min before dosing) and 30, 60, 120, 180, 240, 300, and 360 min after dosing. Subjective ratings of the acute altered state of consciousness using the revised 11 dimension altered states of consciousness questionnaire (11D ASC)were completed 6-7 h after dosing. Psychiatrists adopted a non-directive, supportive approach, allowing the patient to experience a mostly uninterrupted inner "journey". Check-ins (ie, asking the patient how they are feeling) occurred at the same timepoints as the physiological recordings. Tranquilising medications (oral lorazepam and risperidone) were available if necessary. The phenomenology of the acute experience, including accounts of the nature of the therapeutic support provided before, during, and after the experience, and considerations related to the music selection and other aspects of the clinical setting, will be discussed in separate publications. Return transport from the research facility was organised ahead of dosing sessions. Patients were taken to and from the sessions accompanied by a close friend or relative, and had the option of staying overnight in accommodation adjacent to the hospital. Emergency contact details were provided, and patients confi rmed their safe return from the research facility. Patients were contacted via telephone 1 day after their low-dose session to check on their wellbeing and monitor for any adverse events. Patients returned to the research facility 1 day after their high-dose session for a posttreatment fMRI scan lasting 60 min. After the fMRI scan, patients completed interim questionnaires (QIDS, STAI-T, and HAM-D), and were invited back to the research facility where they were met by their psychiatrists to discuss their experience the previous day. Patients attended one further study visit to the research facility 1 week after their high-dose session, during which all baseline questionnaires and assessments were repeated and an opportunity was provided for further psychological debriefi ng (the 1 week follow-up visit). Assessments of HAM-D, MADRS, and GAF were again done by MBo. Subsequent assessments of clinical progress were done via email 2, 3, and 5 weeks after the high-dose session; we assessed only QIDS during subsequent follow-up, so as not to overload the patient. Final follow-up was done remotely at 3 months after the high-dose session, and included QIDS, BDI, STAI-T, and SHAPS. Patients were made aware that they could contact the study psychiatrists at any time if their depression deteriorated. Figuresummarises the screening, intervention, and follow-up procedures in this study.
OUTCOMES
The main objective of this study is to optimise the protocol for the administration of oral psilocybin in this patient group, while gaining an initial impression of treatment effi cacy. The primary outcome measure to assess feasibility was patient-rated subjective intensity of psilocybin's eff ects, which we report on a 0-1 scale. We assessed the safety of the intervention through clinical monitoring during and after dosing sessions, and during 3 months of face-to-face and remote follow-up. We also aimed to assess the preliminary effi cacy of psilocybin in patients with treatment-resistant depression; the primary outcome measure for this endpoint was mean change in the severity of self-reported depressive symptoms (with the 16 item QIDS) from baseline to 1 week after the high-dose psilocybin session. The QIDS was chosen as the primary outcome measure due to its brevity, increasingly widespread use, and validity at 1 week intervals.We chose to assess the primary effi cacy endpoint at 1 week after the high-dose session to allow comparison with previous studies of ketamine infusion for treatment-resistant depression;the low-dose session was conceived a priori as a safety session rather than a treatment session. We also assessed change in BDI, STAI-T, and SHAPS between baseline and 1 week and 3 months of follow-up, and change in HAM-D, MADRS, and GAF between baseline and 1 week of follow-up.
STATISTICAL ANALYSIS
In this feasibility study, we did not perform a formal power calculation. We planned to recruit 12 patients to provide an initial impression of the tolerability and effi cacy of this novel treatment approach. A subsequent protocol amendment (Oct 6, 2015) increased the recruitment to 20 patients to provide statistical power for fMRI imaging. Here, we report fi ndings for the 12 patients initially enrolled; outcome and fMRI data for all 20 patients will be reported separately. Due to the small population, two-tailed Wilcoxon signed ranks tests were performed for non-parametric data. Two-tailed t tests were also performed and the relevant t values are provided in the appendix. We provide 95% CIs around the mean diff erences. We calculated
ROLE OF THE FUNDING SOURCE
The study funder had no role in the design, data collection, analysis, interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had fi nal responsibility for the decision to submit for publication.
RESULTS
Enrolment started on May 1, 2015, and fi nished on Aug 25, 2015. 72 people were initially considered for the study, most of whom self-referred after hearing about this trial through public outreach work (eg, public presentations by the investigators and media reports). 38 were considered appropriate for a telephone screen, from which 18 were invited for a formal screening visit, and 12 were ultimately recruited for the trial (fi gure 2), of whom ten were selfreferrals. Patients' demographic and clinical characteristics are shown in table 1. Nine of the 12 patients met criteria for severe or very severe depression at baseline (BDI score ≥30), with the remaining three patients meeting criteria for moderate depression (BDI score 19 to <30). 11 patients had received some form of psychotherapy before participation in the study. The acute effects of psilocybin were well tolerated by all of the patients and no serious or unexpected adverse events occurred. Mean self-rated intensity of psilocybin experience was 0•51 (SD 0•36) for the lowdose session and 0•75 (0•27) for the high-dose session BDI=Beck Depression Inventory. HAMD-D=Hamilton Depression Rating scale. STAI-T=State-Trait Anxiety Inventory. SSRI=selective serotonin-reuptake inhibitor. SNRI=serotonin-noradrenaline reuptake inhibitor. NDRI=noradrenaline-dopamine-reuptake inhibitor. NSSRI=noradrenaline and specifi c serotonin-reuptake inhibitor. MAOI=monoamine oxidase inhibitor. TCA=tricyclic antidepressant. SARI=serotonin antagonist and reuptake inhibitor. DRI=dopamine-reuptake inhibitor. *One medication from each class, unless otherwise stated.
TABLE 1: BASELINE AND DEMOGRAPHIC CHARACTERISTICS, BY PATIENT
No patients required tranquilising medications (oral lorazepam and risperidone) during the dosing sessions. Psilocybin's acute psychedelic effects typically became detectable between 30 min and 60 min after dosing, peaked between 2 h and 3 h after dosing, and subsided to negligible levels at which the patient could be assessed for discharge at least 6 h after dosing (appendix). Self-rated experiences on the 11D-ASC questionnaire from the two sessions are shown in the appendix. Results from interim patient questionnaires (QIDS, BDI, and STAI-T), done immediately before the low-dose session to monitor for substantial changes since enrolment, did not differ from baseline (data not shown). Interim questionnaires done the day after the high-dose session showed some reduction in depressive symptoms (data for HAM-D in appendix; data for QIDS and STAI-T not shown). The most common adverse events were transient anxiety (mostly mild) during drug onset (n=12), transient confusion or thought disorder (n=9), mild and transient nausea (n=4), and transient headache (n=4; table). These adverse events were expected psychological eff ects of psilocybin. Subacute headache typically presented 1 day after the psilocybin session, and subsided after 1-2 days. Paranoia presented in only one patient, but this was mild and transient. No prolonged psychotic symptoms were observed in any of the patients. One patient contacted the study psychiatrists during the 3 months of follow-up due to deterioration of their depression, and was referred to their general practitioner. QIDS depression scores were signifi cantly reduced from baseline to 1 week and 3 months post-treatment, with the maximum eff ect at 2 weeks (fi gure 3, table). BDI and clinician-administered ratings confi rmed these results (fi gure 4, table). All patients showed some reduction in depression severity at 1 week that was sustained in the majority for 3 months (appendix). According to standard criteria for determining remission (eg, a score of ≤9 on the BDI), eight (67%) of the 12 patients achieved complete remission at 1 week and seven patients (58%) continued to meet criteria for response (50% reduction in BDI score relative to baseline) at 3 months, with fi ve of these (42%) still in complete remission (fi gure 4, table). STAI-T anxiety scores were also signifi cantly reduced at 1 week and 3 months post-treatment, as were SHAPS anhedonia scores for 1 week and 3 months post-treatment (table).
DISCUSSION
In this open-label, single-arm pilot study, we sought to examine the feasibility of administering psilocybin to patients with treatment-resistant depression as a prelude to a larger randomised controlled trial. Our results support Because this was a small-scale feasibility study with an open-label design, strong inferences cannot be made about the treatment's therapeutic effi cacy. However, the data do suggest that further research is warranted. The response rate to psilocybin was 67% (n=8) at 1 week after treatment (HAM-D and BDI), and seven of these eight patients also met criteria for remission. Moreover, 58% (n=7) of the patients maintained their response for 3 months, and 42% (n=5) remained in remission. It is also worth noting that psilocybin has a favourable toxicity profi le and is not associated with compulsive drug-seeking behaviours in animals or human beings. The side-eff ects that we noted were minor, and expected in light of previous studies of psilocybin.Spontaneous recovery in refractory depression is rare, and many of the patients in the present study reported having depression for much of their adult lives (mean estimated illness duration 17•8 years [SD 8]). Key questions for future research therefore should address why the therapeutic eff ect observed in the present study is so large, and if it can be replicated when tighter experimental controls are introduced. Because the treatment in our study consisted of not just two psilocybin administrations but also psychological support before, during, and after these sessions, as well as a positive therapeutic environment for the sessions, the relative eff ects of these factors need to be determined, which can only be done by conducting further trials with appropriate control conditions. A logical next step would be to carry out a placebocontrolled randomised trial in which the level of therapist contact is consistent between conditions. This would enable any between-group diff erences in clinical outcomes to be attributed to psilocybin rather than the psychological support provided. However, a positive interaction between these variables seems likely, and inert placebo-based blinds are known to be ineff ective in studies involving conspicuous experimental interventions, because patients can easily discern whether they are in the active condition or not. Use of an active placebo for the control condition might therefore be worth considering. Additionally, randomised comparative effi cacy trials (eg, with an optional crossover component) incorporating another treatment for refractory depression (eg, ketamine infusion) could also be explored. The magnitude and persistence of the antidepressant eff ects observed here are not incongruent with what has been observed previously with psilocybin in chronic psychiatric conditions. For example, 80% of long-term heavy tobacco smokers demonstrated abstinence from smoking 6 months after two treatment sessions with psilocybin.Alcohol-dependent patients demonstrated signifi cantly reduced drinking behaviours over 8 months after one or two psilocybin sessions.Signifi cantly decreased anxiety and depression scores were observed 3 and 6 months after a single dose of psilocybin in patients with anxiety related to end-stage cancer,and improve ments in wellbeing lasting for more than 1 year were observed in healthy individuals given a single dose of psilocybin.Rapid and enduring decreases in depressive symptoms were also recently found in a small-scale feasibility trial involving the psychedelic brew, ayahuasca.It is important to consider the limitations of this pilot study; for example, although all patients showed some clinical improvements for at least 3 weeks after treatment, and no serious or unexpected adverse reactions were observed, enduring improvements beyond 3 weeks were not observed universally, and fi ve of the 12 patients showed a degree of relapse at 3 months. One should be cautious of the potential for infl ated eff ect sizes in early trials, particularly when the sample size is small. That all patients showed some improvement in their depressive symptoms for up to 3 weeks after treatment could be suggestive of an expectancy bias. It may also be relevant that most patients in this trial were self-referring and, thus, actively sought this treatment. Psychedelics are known to promote suggestibility,which might have further enhanced positive outcomes. Future double-blind randomised controlled trials could address the role of expectancy and suggestibility by measuring and controlling these variables. For example, patients could be asked about their pre-treatment expectations, suggestions could be controlled between conditions, and outcomes from self-referred patients could be compared with those from patients referred via clinicians. From a more pragmatic perspective, if expectancy or suggestibility are found to be infl uential in the context of psychedelic therapy, they could be treated as exploitable components of the treatment model rather than confounding variables. Serotonergic antidepressants have been found to downregulate the primary receptor target of psilocybin (the 5-HT 2A receptor) and attenuated subjective responses to psychedelics have previously been reported in individuals chronically medicated with serotonergic antidepressants.Thus, patients may be required to withdraw from concurrent antidepressant medication before receiving psilocybin and this should only ever be done with care. In conclusion, we sought to assess the safety and tolerability of psilocybin plus psychological support in patients with unipolar treatment-resistant depression. Our fi ndings support the feasibility of this approach and the magnitude and duration of the post-treatment reductions in symptom severity motivate further controlled research. Psilocybin has a novel pharmacological action in comparison with currently available treatments for depression (ie, 5-HT 2A receptor agonism) and thus could constitute a useful addition to available therapies for the treatment of depression.
CONTRIBUTORS
RLC-H and DJN designed the study and RLC-H wrote the report. RLC-H coordinated the study, and collected and analysed the data. MBo was the lead psychiatrist on the trial. MBo, JR, CMJD, DE, and MBl provided psychological support for the patients. All authors critically revised the report or contributed important intellectual content.
DECLARATION OF INTERESTS
DT has received research funding and lecture honoraria from Servier, and lecture honoraria from Lundbeck. The other authors declare no competing interests.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicsopen labelfollow up
- Journal
- Compound
- TopicsAnxiety DisordersDepressive DisordersAdolescentsMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Obsessive-Compulsive Disorder (OCD)Alcohol Use Disorder (AUD)Tobacco/Nicotine Use Disorder (TUD)Substance Use Disorders (SUD)Headache Disorders (Cluster & Migraine)Palliative & End-of-Life DistressSafety & Risk ManagementChronic Pain
- Authors
- APA Citation
References (11)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Bouso, J. C., González, D., Fondevila, S. et al. · PLOS ONE (2012)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)
Show all 11 referencesShow fewer
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Cited By (350)
Papers in Blossom that reference this study
Pasquini, L., Vohryzek, J., Escrichs, A. et al. · Human Brain Mapping (2026)
Jajcay, N., Vejmola, Č., Korčák, J. et al. · Biorxiv (2026)
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C. et al. · Journal of Affective Disorders (2026)
Kelly, C. M., Fradet, M., Bostian, C. M. et al. · Journal of Affective Disorders (2026)
Mertens, L. J., Betzler, F., Brand, M. et al. · Psychotherapy and Psychosomatics (2026)
Yngwe, H., Plavén-Sigray, P., Ekman, C. J. et al. · JAMA Network Open (2026)
Tarailis, P., Griskova-Bulanova, I. · Biorxiv (2026)
Artna, E., Sandhu, G., Chisamore, N. et al. · Psychiatry Research (2026)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · Journal of Affective Disorders (2026)
Gubser, L. P., Trippel, A. S., Zoelch, N. et al. · Brain Research Bulletin (2026)
Show all 350 papersShow fewer
Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)
Gregorio, G. D., Basset, S., Manmohan, H. et al. · Research Square (2026)
Goldy, S. P., Sepeda, N. D., Hilbert, S. N. et al. · Psychiatry Research (2026)
Marsden, J., Kelleher, M., Dunbar, F. et al. · Addiction (2025)
Prochazkova, L., van Elk, M., Marschall, J. et al. · Neuropsychopharmacology (2025)
Ellis, S., Bostian, C., Donnelly, A. et al. · Journal of Affective Disorders (2025)
Meikle, S., Carter, O., Liknaitzky, P. et al. · Therapeutic Advances in Psychopharmacology (2025)
Mu, F., Zaczek, H., Becker, A. M. et al. · Med (2025)
Socoró-Garrigosa, M., Sanz Perl, Y., Kringelbach, M. L. et al. · Annals of the New York Academy of Sciences (2025)
Downey, A. E., Szigeti, B., Bradley, E. R. et al. · OSF Preprints (2025)
Williams, Z. J., Barnett, H., Szigeti, B. · OSF Preprints (2025)
Wall, M. B., Demetriou, L., Giribaldi, B. et al. · American Journal of Psychiatry (2025)
Harding, R., Singer, N., Wall, M. B. et al. · Molecular Psychiatry (2025)
Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)
Rieser, N. M., Bitar, R., Halm, S. et al. · EClinicalMedicine (2025)
Chisamore, N., Kaczmarek, E. S., Doyle, Z. et al. · Canadian Journal of Psychiatry (2025)
Gumpper, R. H., Jain, M. K., Kim, K. et al. · Nature Communications (2025)
Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)
Becker, A. M., Humbert-Droz, M., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)
Meshkat, S., Kaczmarek, E., Doyle, Z. et al. · Psychedelic Medicine (2025)
Larsen, K., Lindberg, U., Ozenne, B. et al. · Journal of Cerebral Blood Flow and Metabolism (2025)
Irrmischer, M., Puxty, D. J., Deijen, J. B. et al. · Psychopharmacology (2025)
Godfrey, K., Weiss, B., Zhang, X. et al. · Neuroscience Applied (2025)
Ellis, S., Bostian, C., Feng, W. et al. · Journal of Affective Disorders (2025)
Enriquez-Geppert, S,, Lietz, M. P., O'Higgins, F. · Philosophical Transactions of the Royal Society B (2024)
Fleury, S., Nautiyal, K. M. · Biorxiv (2024)
Erritzoe, D., Barba, T., Greenway, K. T. et al. · EClinicalMedicine (2024)
Vizeli, P., Studerus, E., Holze, F. et al. · Translational Psychiatry (2024)
Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)
Salvetti, G., Saccenti, D., Moro, A. S. et al. · Brain Sciences (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Nicol, G. E. · Nature (2024)
Robinson, O., Evans, J., Luke, D. et al. · Frontiers in Psychology (2024)
Rieser, N. M. · Biological Psychiatry (2024)
Gordon, A. R., Carrithers, B. M., Pagni, B. A. et al. · Research Square (2024)
Moujaes, F., Lisa, J., Rahmati, M. et al. · eLife (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Meling, D., Ehrenkra, R., Nayak, S. et al. · Psychoactives (2024)
Wong, S., Kwan, A. T. H., Teopiz, K. M. et al. · Journal of Affective Disorders (2024)
Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)
Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)
Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)
Rosenblat, J. D., Meshkat, S., Doyle, Z. et al. · Med (2024)
Copa, D., Erritzoe, D., Giribaldi, B. et al. · Journal of Affective Disorders (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)
Barba, T., Kettne, H., Radu, C. et al. · Scientific Reports (2024)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · Scientific Reports (2024)
Solaja, I., Haldane, K., Mason, N. et al. · Neuroscience and Biobehavioral Reviews (2024)
Mediano, P. A. M., Rosas, F. E., Timmermann, C. et al. · ACS Chemical Neuroscience (2024)
James, E., Erritzoe, D., Benway, T. et al. · Frontiers in Psychiatry (2024)
Cherian, K. N., Keynan, J. N., Anker, L. et al. · Nature Medicine (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Straumann, I., Holze, F., Becker, A. M. et al. · Neuroscience Applied (2024)
Nicholas, C. R., Horton, D. M., Malicki, J. et al. · Psychedelic Medicine (2023)
Haikazian, S., Chen-Li, D., Johnson, D. et al. · Psychiatry Research (2023)
Rieser, N. M., Gubser, L. P., Moujaes, F. et al. · Scientific Reports (2023)
Enriquez-Geppert, S,, Krc, J., O'Higgins, F., Lietz, M. P. · OSF Preprints (2023)
Lebedev, A. V., Acar, K., Horntvedt, O. et al. · Scientific Reports (2023)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Wall, M. B., Harding, R., Zafar, R. et al. · Molecular Psychiatry (2023)
Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)
Nayak, S., Jackson, H., Sepeda, N. D. et al. · Frontiers in Psychiatry (2023)
Mortaheb, S., Fort, L. D., Mason, N. L. et al. · Biological Psychiatry (2023)
Tyagi, R., Saraf, T. S., Canal, C. E. · ACS Pharmacology and Translational Science (2023)
Xin, Y., Armstrong, S. B., Averill, L. A. et al. · Psychology of Consciousness Theory Research and Practice (2023)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Simonsson, O., Carhart-Harris, R., Davis, A. K. et al. · Psychiatry Research (2023)
Neubert, J. J., Anderson, K., Mason, N. L. · Psyarxiv (2023)
Abrams, S. K., Rabinovitch, B. S., Zafar, R. et al. · Neurotherapeutics (2023)
Pereira, L. · European Neuropsychopharmacology (2023)
Peck, S. K., Shao, S., Grue, T. et al. · Nature Medicine (2023)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)
Goodwin, G. M., Croal, M., Feifel, D. et al. · Neuropharmacology (2023)
Wall, M. B., Lam, C., Ertl, N. et al. · Journal of Affective Disorders (2023)
Romeo, B., Fauvel, B., Verroust, V. et al. · Journal of Psychoactive Drugs (2023)
Low, F., Earleywine, M. · Journal of Psychoactive Drugs (2023)
Rossi, G. N., Rocha, J. M., Osório, F. L. et al. · Journal of Clinical Psychopharmacology (2023)
Muthukumaraswamy, S. · Psyarxiv (2023)
Weiss, B., Wingert, A., Erritzoe, D. et al. · Scientific Reports (2023)
Bloesch, E. K., Davis, A. K., Domoff, S. E. et al. · Psyarxiv (2023)
Weiss, B., Ginige, I., Shannon, L. et al. · Psychological Medicine (2023)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)
Feusner, J. D., Wheaton, M. G., Gomez, G. J. et al. · Journal of Psychiatric Research (2023)
Herzog, R., Mediano, P. A. M., Rosas, F. E. et al. · Scientific Reports (2023)
Weiss, B., Sleep, C., Miller, J. D. et al. · Journal of Personality Disorders (2023)
Goodwin, G. M. · Journal of Affective Disorders (2023)
Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)
Kaup, K. K., Vasser, M., Tulver, K. et al. · Frontiers in Psychiatry (2023)
Nikolaidis, A., Lancelotta, R., Gukasyan, N. et al. · Journal of Affective Disorders (2023)
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Moreton, S. G., Arena, A. F., Foy, Y. et al. · Death Studies (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Holze, F., Gasser, P., Müller, F. et al. · Biological Psychiatry (2023)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Rudin, D., Areesanan, A., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)
DellaCrosse, M., Pleet, M. M., Morton, E. et al. · PLOS ONE (2022)
Breant, B., Mengual, J. P., Bannerman, D. et al. · Biorxiv (2022)
Desai, S., Jain, V., Xavier, S. et al. · Children (2022)
Passie, T., Guss, J., Kraehenmann, R. · Frontiers in Psychiatry (2022)
Kelmendi, B., Kichuk, S. A., DePalmer, G. et al. · Heliyon (2022)
MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)
Ortiz Bernal, A. M., Raison, C. L., Lancelotta, R. et al. · Frontiers in Psychiatry (2022)
Spriggs, M. J., Murphy-Beiner, A., Murphy, R. et al. · Psychological Medicine (2022)
Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Zhang, J. C., Yao, W., Hashimoto, K. · Neuropharmacology (2022)
Kopra, E., Cleare, A. J., Rucker, J. et al. · Journal of Affective Disorders (2022)
Madsen, M. K., Ozenne, B., Armand, S. et al. · Frontiers in Psychology (2022)
Cruzat, J., Perl, Y. S., Escrichs, A. et al. · Network Neuroscience (2022)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Kałużna, A., Schlosser, M., Gulliksen Craste, E. et al. · Journal of Psychedelic Studies (2022)
Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)
Mellner, C., Dahlen, M., Simonsson, O. · International Journal of Environmental Research and Public Health (2022)
Kaypak, A. C., Raz, A. · Transcultural Psychiatry (2022)
Glynos, N., Fields, C. W., Barron, J. et al. · Journal of Psychoactive Drugs (2022)
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)
Johnson, M. W. · Current Topics in Behavioral Neurosciences (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Cavarra, M., Falzone, A., Ramaekers, J. G. et al. · Frontiers in Psychology (2022)
D’Souza, D. C., Syed, S. A., Safi-Aghdam, H. et al. · Neuropsychopharmacology (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Argento, E., Goldenberg, S., Deering, K. et al. · Drug and Alcohol Dependence (2022)
Johnson, S., Letheby, C. · Journal of Psychedelic Studies (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Yaden, D. B., Earp, D., Graziosi, M. et al. · Frontiers in Psychology (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Barr, A. M., Huang, J., Pham, M. et al. · Frontiers in Psychiatry (2022)
Soares, C. M., Leite, A., Pinto, M. · Journal of Psychoactive Drugs (2022)
Gill, H., Puramat, P., Patel, P. et al. · Psychiatry Research (2022)
Oehen, P., Gasser, P. · Frontiers in Psychiatry (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)
Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)
Shaw, L., Rea, K., Lachowsky, N. J. et al. · Journal of Psychoactive Drugs (2022)
Raison, C. L., Jain, R., Jain, S. et al. · Frontiers in Psychiatry (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Yu, C. L., Liang, C. S., Yang, F. et al. · Journal of Clinical Medicine (2022)
Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)
Olson, D. E. · Biochemistry (2022)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
Hadar, A., David, J., Shalit, N. et al. · Journal of Psychoactive Drugs (2022)
Altman, B. R., Earleywine, M., De Leo, J. · Journal of Psychoactive Drugs (2022)
Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)
Mertens, L. J., Koslowski, M., Betzler, F. et al. · Neuroscience Applied (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Whitfield, H. J. · Frontiers in Psychiatry (2021)
Olson, D. E. · Journal of Neurochemistry (2021)
Rucker, J., Jafari, H., Mantingh, T. et al. · BMJ Open (2021)
Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L. et al. · Frontiers in Psychology (2021)
Becker, A. M., Holze, F., Grandinett, T. et al. · Clinical Pharmacology and Therapeutics (2021)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Kuc, J., Kettner, H., Rosas, F. E. et al. · Psychopharmacology (2021)
Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)
Johnstad, P. G. · Journal of Psychedelic Studies (2021)
Lafrance, A., Strahan, E., Bird, B. M. et al. · Journal of Humanistic Psychology (2021)
Vejmola, Č., Tylš, F., Piorecká, V. et al. · Translational Psychiatry (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
De La, M., Revenga, F., Zhu, B. et al. · Cell Reports (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Brennan, W., Jackson, M. A., MacLean, K. A. · Journal of Humanistic Psychology (2021)
Basedow, L. A., Riemer, T. G., Reiche, S. et al. · Frontiers in Pharmacology (2021)
McGovern, H., Leptourgos, P., Hutchinson, B. et al. · Psyarxiv (2021)
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Kuiperes, Z., Schreiber, R. · Neurobiology of Learning and Memory (2021)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Davis, A. K., Xin, Y., Sepeda, N. D. et al. · Chronic Stress (2021)
Hübner, S., Haijen, E. C. H. M., Kaelen, M. et al. · Journal of Medical Internet Research (2021)
Dollar, C. B. · Qualitative Criminology (2021)
Lebedev, A. V., Acar, K., Garzón, B. et al. · Scientific Reports (2021)
Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)
Savino, A., Nichols, C. D. · Biorxiv (2021)
Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)
Bird, C. I. V., Modlin, N. L., Rucker, J. · International Review of Psychiatry (2021)
Lu, J., Tjia, M., Mullen, B. et al. · Molecular Psychiatry (2021)
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. et al. · Hypertension (2021)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Rodrigues, L. S., Rossi, G. N., Rocha, J. M. et al. · European Archives of Psychiatry and Clinical Neuroscience (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Gard, D. E., Pleet, M. M., Bradley, E. R. et al. · Journal of Affective Disorders (2021)
Savalia, N., Shao, L-X,, Kwan, A. C. · Trends in Neuroscience (2021)
Nigam, K. B., Pandurangi, A. K. · SN Comprehensive Clinical Medicine (2021)
Kettner, H., Rosas, F. E., Timmermann, C. et al. · Frontiers in Pharmacology (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Tagliazucchi, E., Zamberlan, F., Cavanna, F. et al. · Frontiers in Psychiatry (2021)
Nayak, S., Gukasyan, N., Barrett, F. S. et al. · Pharmacopsychiatry (2021)
Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)
Nielson, E. M., Tai, S. J., Lennard-Jones, M. et al. · Frontiers in Psychiatry (2021)
Lawrence, D. W., Sharma, B., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2021)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)
Nkadimeng, S. M., Steinmann, C. M. L., Eloff, J. N. · Scientific Reports (2020)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)
Kanen, J. W., Luo, Q., Kandroodi, M. R. et al. · Psychological Medicine (2020)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Dudysová, D., Janků, K., Šmotek, M. et al. · Frontiers in Pharmacology (2020)
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Goldberg, S. B., Shechet, B., Nicholas, C. R. et al. · Psychological Medicine (2020)
Doss, M. K., May, D. G., Johnson, M. W. et al. · Scientific Reports (2020)
Gill, H., Gill, B., Chen-Li, D. et al. · Expert Review of Neurotherapeutics (2020)
Varker, T., Watson, L., Gibson, K. et al. · Journal of Psychoactive Drugs (2020)
Greb, A. C., Vargas, M. V., Duim, W. C. et al. · ACS Pharmacology and Translational Science (2020)
Rubin-Kahana, D. S., Hassan, A. N., Le Foll, B. · Journal of Addiction Medicine (2020)
Vargas, A. S., Luís, Â., Barroso, M. et al. · Biomedicines (2020)
Kim, K., Che, T., Panova, O. et al. · Cell (2020)
Kelly, J. R., Crockett, M. T., Alexander, L. et al. · Irish Journal of Psychological Medicine (2020)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Weston, N. M., Gibbs, D., Bird, C. I. V. et al. · Depression and Anxiety (2020)
Kargbo, R. B., Sherwood, A. R., Walker, A. et al. · ACS Omega (2020)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)
Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Greif, A., Šurkala, M. · Medicine Health Care and Philosophy (2020)
Smith, W. R., Sisti, D. · Journal of Medical Ethics (2020)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)
Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Benko, J., Vranková, S. · Molecules (2020)
Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)
Bienemann, B., Ruschel, N. S., Campos, M. L. et al. · PLOS ONE (2020)
Lewis, C. R., Preller, K. H., Braden, B. B. et al. · Biomedicines (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Mason, N. L., Feilding, A., Ramaekers, J. G. · European Neuropsychopharmacology (2020)
Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)
Voineskos, D., Daskalakis, Z. J., Blumberger, D. M. · Neuropsychiatric Disease And Treatment (2020)
Nichols, C. D., Hendricks, P. S. · Handbook of Behavioral Neuroscience (2020)
Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)
Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Adams, A. M., Kaplan, N. A., Wei, Z. et al. · Metabolic Engineering (2019)
Sartori, S. B., Singewald, N. · Pharmacology and Therapeutics (2019)
Andersson, M., Kjellgren, A. · Harm Reduction Journal (2019)
Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F. et al. · Frontiers in Pharmacology (2019)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Lord, L. D., Expert, P., Atasoy, S. et al. · NeuroImage (2019)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)
Sakloth, F., Leggett, E., Moerke, M. J. et al. · Experimental and Clinical Psychopharmacology (2019)
Nutt, D. J. · Dialogues in Clinical Neuroscience (2019)
Jefsen, O., Højgaard, K., Christiansen, S. L. et al. · Acta Neuropsychiatrica (2019)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Scott, G., Carhart-Harris, R. L. · Neuroscience of Consciousness (2019)
Davis, A. K., So, S., Lancelotta, R. et al. · The American Journal of Drug and Alcohol Abuse (2019)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Stenbæk, D. S., Kristiansen, S., Burmester, D. et al. · Human Brain Mapping (2019)
Johnson, M. W. · International Review of Psychiatry (2018)
Passie, T., Brandt, S. D. · New Psychoactive Substances (2018)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Timmermann, C., Spriggs, M. J., Kaelen, M. et al. · Neuropharmacology (2018)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Prochazkova, L., Lippelt, D. P., Colzato, L. S. et al. · Psychopharmacology (2018)
Lyons, T., Carhart-Harris, R. L. · Frontiers in Psychology (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)
Flanagan, T. W., Nichols, C. D. · International Review of Psychiatry (2018)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Geiger, H. A., Wurst, M. G., Daniels, R. N. · ACS Chemical Neuroscience (2018)
Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)
Barnett, B. S., Siu, W. O., Pope Jr, H. G. · Journal of Nervous and Mental Disease (2018)
Mason, N. L., Kuypers, K. P. C. · Journal of Psychedelic Studies (2018)
Cassels, B. K., Sáez-Briones, P. · ACS Chemical Neuroscience (2018)
Gabay, A. S., Carhart-Harris, R. L., Mazibuko, N. et al. · Scientific Reports (2018)
Cameron, L. P., Benson, C. J., Dunlap, L. E. · ACS Chemical Neuroscience (2018)
Dorsen, C., Palamar, J., Shedlin, M. G. · Addiction Research and Theory (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Moroz, M., Carhart-Harris, R. L. · IEEE Explore (2018)
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Belouin, S. J., Henningfield, J. E. · Neuropharmacology (2018)
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H. et al. · Frontiers in Pharmacology (2018)
Reiche, S., Hermle, L., Gutwinski, S. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Adams, T. · Biorxiv (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Barsuglia, J. P., Polanco, M., Palmer, R. et al. · Progress in Brain Research (2018)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Atasoy, S., Leor, R., Kaelen, M. et al. · Scientific Reports (2017)
Riga, M. S., Llad O-Pelfort, L., Artigas, F. et al. · Neuropharmacology (2017)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Liu, F., Gong, Y., Wang, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Argento, E., Strathdee, S. A., Tupper, K. et al. · BMJ Open (2017)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Bøhling, F. · International Journal of Drug Policy (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Slevc, L. R., Barrett, F. S., Robbins, H. et al. · Frontiers in Psychology (2017)
Larsen, J. K. · Nordic Journal of Psychiatry (2017)
Kaelen, M., Lorenz, R., Barrett, F. S. et al. · Biorxiv (2017)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Thomas, K., Malcolm, B., Lastra, D. · Journal of Psychoactive Drugs (2017)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Nour, M. R., Evans, J., Carhart-Harris, R. L. · Journal of Psychoactive Drugs (2017)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Kaelen, M. · Imperial College London (2017)
Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)
Nour, M. R., Carhart-Harris, R. L. · British Journal of Psychiatry (2017)
Bryson, A., Carter, O., Norman, T. et al. · International Journal of Neuropsychopharmacology (2017)
Morgan, C. J. A., McAndrew, A., Stevens, T. et al. · Current Opinion in Behavioral Sciences (2017)
Idell, R. D., Florova, G., Komissarov, A. A. et al. · Medical Hypotheses (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Sweat, N. W., Bates, L. W., Hendricks, P. S. · Journal of Psychoactive Drugs (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)